Cancer 55 : 23032316 Sato H, Tamba M, Ishii T, Bannai S (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins
In 2025, the company reported a strong +17.08% YoY revenue growth, largely driven by its core therapies: Jardiance ($10.33B) continues to lead as a blockbuster across diabetes, heart failure, and kidney disease, Ofev ($4.49B) remains a key growth driver in pulmonary fibrosis, while Trajenta ($1.72B) continues to contribute despite a mature lifecycle - highlighting a portfolio balancing high-growth and established assets
developed tissue specific KOs of HSL in adipocytes and liver
Researchers believe the simpler delivery method could reshape treatment habits
This method could work on almost any fat deposit in the body, even deep fat that other injections cant reach
Sin embargo, son frmacos que comparten mecanismos de accin similares a los de la semaglutida, lo que plantea interrogantes sobre la posibilidad de que tambin puedan asociarse a riesgos oculares como la Noiana